General
Preferred name
MISOPROSTOL
Synonyms
misoprostol (methyl ester) ()
Misoprostol component of arthrotec ()
Mysodelle ()
SC-29333 ()
Topogyne ()
Cytotec ()
11.beta.-Misoprostol ()
Misoprostol-d5 ()
P&D ID
PD008617
CAS
59122-46-2
103601-27-0
58717-36-5
Tags
available
drug
prodrug
Approved by
FDA
First approval
1988
Drug indication
hemorrhage
Medical abortion
Drug Status
approved
investigational
Max Phase
4.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
The INN-assigned approved drug misoprostol is a racemic mixture of two epimers and their enantiomers. For more information, please see the ChEBI link above. Note that the INN-assigned structure represents the methyl ester form of the compound as which the drug is administered. The drug is then converted in vivo to the active metabolite .
(GtoPdb)
MOA
Misoprostol seems to inhibit gastric acid secretion by a direct action on the parietal cells through binding to the prostaglandin receptor. The activity of this receptor is mediated by G proteins which normally activate adenylate cyclase. The indirect inhibition of adenylate cyclase by Misoprostol may be dependent on guanosine-5’-triphosphate (GTP). The significant cytoprotective actions of misoprostol are related to several mechanisms. These include: 1. Increased secretion of bicarbonate, 2. Considerable decrease in the volume and pepsin content of the gastric secretions, 3. It prevents harmful agents from disrupting the tight junctions between the epithelial cells which stops the subsequent back diffusion of H+ ions into the gastric mucosa, 4. Increased thickness of mucus layer, 5. Enhanced mucosal blood flow as a result of direct vasodilatation, 6. Stabilization of tissue lysozymes/vascular endothelium, 7. Improvement of mucosal regeneration capacity, and 8. Replacement of prostaglandins that have been depleted as a result of various insults to the area. ; Misoprostol has also been shown to increase the amplitude and frequency of uterine contractions during pregnancy via selective binding to the EP-2/EP-3 prostanoid receptors.
INDICATION
Indicated for the treatment of ulceration (duodenal, gastric and NSAID induced) and prophylaxis for NSAID induced ulceration.; Misoprostol is also indicated for other uses that are not approved in Canada, including the medical termination of an intrauterine pregnancy used alone or in combination with methotrexate,as well as the induction of labour in a selected population of pregnant women with unfavourable cervices. This indication is avoided in women with prior uterine surgery or cesarean surgery due to an increased risk of possible uterine rupture. Misoprostol is also used for the prevention or treatment of serious postpartum hemorrhage.
DESCRIPTION
Misoprostol is a synthetic prostaglandin E1 analog that stimulates prostaglandin E receptors. It is used to reduce the risk of NSAID-induced gastric ulcers.
(Enamine Bioactive Compounds)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
24
ChEMBL Approved Drugs
ChEMBL Drugs
Concise Guide to Pharmacology 2017/18
Concise Guide to Pharmacology 2019/20
Concise Guide to Pharmacology 2021/22
Concise Guide to Pharmacology 2023/24
Concise Guide to Pharmacology 2025/26
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
Enamine Bioactive Compounds
Guide to Pharmacology
JUMP-Target 1 Compound Set
NCATS Inxight Approved Drugs
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
328
Molecular Weight
382.27
Hydrogen Bond Acceptors
5
Hydrogen Bond Donors
2
Rotatable Bonds
13
Ring Count
1
Aromatic Ring Count
0
cLogP
3.95
TPSA
83.83
Fraction CSP3
0.82
Chiral centers
4.0
Largest ring
5.0
QED
0.29
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Member status
virtual
MOA
PTGER1 agonist
PTGER2 agonist
PTGER3 agonist
prostanoid receptor agonist
Indication
duodenal ulcer disease
Target
PTGER2, PTGER3, PTGER4, PTGIR
PTGIR
Therapeutic Class
Abortifacient Agents
Source data

